Celera Genomics Gets NIH Grant To Sequence Rat Genome
Dow Jones Newswires
ROCKVILLE, Md. -- Celera Genomics Group-Applera Corp. (CRA), in collaboration with Baylor College of Medicine, received an NIH grant to sequence four-fold coverage of the rat genome within two years.
In a press release Wednesday, Celera said Genome Therapeutics Corp. (GENE), the Institute for Genomic Research, and the University of British Columbia also will participate in the project.
Celera said the rat genome, with about 3 billion base pairs in size, is similar to the size of the human genome, adding that the rat is a key experimental animal for many areas of biomedical research and is important for the pharmaceutical industry in understanding potential toxicology for medications.
New York Stock Exchange-listed shares of Celera recently traded at $42.30, up $1.15, or 2.8%, on composite volume of 678,100 shares. Average daily volume is 1.7 million shares.
Celera, which had revenue of $38.6 million for the six months ended Dec. 31, provides genomic and related medical information.
Company Web site applera.com
-Karen M. Chow; Dow Jones Newswires; |
